A phase II trial of neoadjuvant erlotinib in patients with muscle‐invasive bladder cancer undergoing radical cystectomy: clinical and pathological results
暂无分享,去创建一个
E. Wallen | William Y. Kim | Y. Whang | J. Fielding | M. Nielsen | R. Pruthi | Angela B Smith | P. Godley | S. Heathcote | G. Grigson | W. Rathmell | Heather Schultz
[1] J. Panetta,et al. Pharmacokinetics of Erlotinib for the Treatment of High‐Grade Glioma in a Pediatric Patient with Cystic Fibrosis: Case Report and Review of the Literature , 2009, Pharmacotherapy.
[2] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[3] K. Baggerly,et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. , 2008, The Journal of urology.
[4] P. Schellhammer,et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.
[5] J. Brahmer,et al. “Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When?” , 2007, Current treatment options in oncology.
[6] G. de Rosa,et al. Expression of apoptosis-related markers in malignant epithelial tumours of the lacrimal gland and their relation to clinical outcome , 2007, British Journal of Ophthalmology.
[7] Yair Lotan,et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. , 2007, European urology.
[8] G. Clark,et al. Effects of Smoking on the Pharmacokinetics of Erlotinib , 2006, Clinical Cancer Research.
[9] Michelle L. Reyzer,et al. Short course of EGF receptor tyrosine kinase inhibitor erlotinib (OSI-774) reduces tumor cell proliferation and active MAP kinase in situ in untreated operable breast cancers: A strategy for patient selection into phase II trials with signaling inhibitors , 2005 .
[10] S. Fosså,et al. Expression of the epidermal growth factor receptor family in normal and malignant urothelium , 2005, BJU international.
[11] N. Normanno,et al. The ErbB receptors and their ligands in cancer: an overview. , 2005, Current drug targets.
[12] A. Halpern,et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. , 2005, The oncologist.
[13] D. Polsky,et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients , 2004, International journal of cancer.
[14] G. Hall,et al. Systemic chemotherapy for patients with bladder cancer--current controversies and future directions. , 2004, Cancer treatment reviews.
[15] J. Lunec,et al. Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2 , 2004, British Journal of Cancer.
[16] R. Goldberg,et al. New targeted therapies in gastrointestinal cancers , 2003, Current treatment options in oncology.
[17] Nicholas J Vogelzang,et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.
[18] C. Dinney,et al. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. , 2003, Critical reviews in oncology/hematology.
[19] Ruth Katz,et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.
[20] J. Mellon,et al. Epidermal growth factor receptor and bladder cancer , 2002, Postgraduate medical journal.
[21] Clinic Pio Xi,et al. Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role? , 2002 .
[22] T. Tzai,et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] S. Groshen,et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Theodorescu,et al. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression , 1998, International journal of cancer.
[25] C. Bucana,et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] D. Neal,et al. Original Articles: Bladder Cancer , 1995 .
[27] E. Messing. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. , 1990, Cancer research.
[28] A. Harris,et al. The epidermal growth factor receptor and the prognosis of bladder cancer , 1990, Cancer.
[29] E. Messing,et al. Normal and malignant human urothelium: in vitro effects of epidermal growth factor. , 1987, Cancer research.
[30] M. Bennett,et al. EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURS , 1985, The Lancet.
[31] A. Harris. Letter: Vitamin-C-induced hyperoxaluria. , 1976, Lancet.